Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Liabilities and Shareholders Equity (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $154.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 13.22% to $154.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $481.3 million through Dec 2025, down 24.82% year-over-year, with the annual reading at $154.4 million for FY2025, 13.22% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $154.4 million at Precision Biosciences, up from $93.5 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $297.2 million in Q2 2022, with the low at $93.5 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $187.6 million, with a median of $181.5 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 40.85% in 2021, then plummeted 39.52% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $211.5 million in 2021, then increased by 12.61% to $238.2 million in 2022, then plummeted by 32.91% to $159.8 million in 2023, then fell by 14.64% to $136.4 million in 2024, then rose by 13.22% to $154.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $154.4 million, $93.5 million, and $108.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.